A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy
详细信息 查看全文
- 作者：Tsuyoshi Shirakawa (1) (2)
Ken Kato (1)
Kengo Nagashima (3)
Akiko Nishikawa (1)
Ryoichi Sawada (1)
Naoki Takahashi (1)
Hirokazu Shoji (1)
Yusuke Sasaki (1)
Yoshitaka Honma (1)
Satoru Iwasa (1)
Atsuo Takashima (1)
Natsuko Okita (1)
Tetsuya Hamaguchi (1)
Yasuhide Yamada (1)
Yasuhiro Shimada (1) - 关键词：Docetaxel ; Esophageal squamous cell carcinoma ; Paclitaxel ; Prognostic factor ; Second ; line chemotherapy
- 刊名：Cancer Chemotherapy and Pharmacology
- 出版年：2014
- 出版时间：December 2014
- 年：2014
- 卷：74
- 期：6
- 页码：1207-1215
- 全文大小：424 KB
- 参考文献：1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11-0 CrossRef
2. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-0 CrossRef
3. Demographic statistics. Ministry of Health, Labour and Welfare, Japan, 2006
4. Hayashi K, Ando N, Watanabe H et al (2001) Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) trial (JCOG9407). Jpn J Clin Oncol 31(9):419-23 CrossRef
5. Ilson DH (2003) Oesophageal cancer: new developments in systemic therapy. Cancer Treat Rev 29:525-32 CrossRef
6. Bleiberg H, Conroy T, Paillot B et al (1997) Randomized phase II study of cisplatin and 5-FU versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33:1216-220 CrossRef
7. Vanhoefer U, Rougier P, Wilke H et al (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 18:2648-657
8. Muro K, Hamaguchi T, Ohtsu A et al (2004) A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15(6):955-59 CrossRef
9. Kato K, Tahara M, Hironaka S et al (2011) A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol 67(6):1265-272 CrossRef
10. Heath EI, Urba S, Marshall J et al (2002) Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Investig New Drugs 20(1):95-9 CrossRef
11. Anderson SE, O’Reilly EM, Kelsen DP et al (2003) Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer. Cancer Invest 21:512-16 CrossRef
12. Thallinger CMR, Raderer M, Hejna M (2011) Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol 29(35):4709-714 CrossRef
13. Hirao M, Ando N, Tsujinaka T et al (2011) Influence of preoperative chemotherapy for advanced thoracic oesophageal squamous cell carcinoma on perioperative complications. Br J Surg 98(12):1735-741 CrossRef
14. Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349:2241-252 CrossRef
15. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-47 CrossRef
16. Cox DR (1972) Regression models and life-tables. J R Stat Soc B 34:187-02
17. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343-46 CrossRef
18. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-81 CrossRef
19. Peto R, Peto J (1972) - 作者单位：Tsuyoshi Shirakawa (1) (2)
Ken Kato (1)
Kengo Nagashima (3)
Akiko Nishikawa (1)
Ryoichi Sawada (1)
Naoki Takahashi (1)
Hirokazu Shoji (1)
Yusuke Sasaki (1)
Yoshitaka Honma (1)
Satoru Iwasa (1)
Atsuo Takashima (1)
Natsuko Okita (1)
Tetsuya Hamaguchi (1)
Yasuhide Yamada (1)
Yasuhiro Shimada (1)
1. Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
2. Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka-shi, 811-1395, Japan
3. Clinical Research Center, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8677, Japan - ISSN：1432-0843
文摘
Introduction Fluoropyrimidine plus platinum (FP)-based chemotherapy has been widely used as a first-line regimen for advanced or recurrent esophageal cancer, and taxanes have shown efficacy after FP-based chemotherapy, but there is no standard regimen for second-line chemotherapy (SLC). We retrospectively investigated the clinical features of taxane therapy in SLC for esophageal squamous cell carcinoma (ESCC). Methods The selection criteria were pathologically proven ESCC; advanced or recurrent disease previously treated with FP at our hospital; performance status (PS) 0-; and adequate organ function. Docetaxel (DTX) was administered 3-weekly at 70?mg/m2. Paclitaxel (PTX) was administered at 100?mg/m2 weekly for 6?weeks, with 1?week’s rest. Results The analysis covered 163 patients from August 2006 to June 2012. Median age was 64?years (range 37-3: DTX group 132 patients and PTX group 31). Progression-free survival and median overall survival (OS) were 2.3 and 6.1?months, respectively, with PTX and 2.3 and 5.3?months with DTX. Response rates were 20.7?% for PTX and 5.9?% for DTX. The rate of grades 3- neutropenia was higher with DTX (32.6?%) than with PTX (16.1?%). Grade 3 febrile neutropenia was seen in 6.1?% of DTX recipients but in no PTX group. According to multivariate analyses of OS, PS 2, number of metastatic sites ?, and CRP ??mg/dL were independent predictors of poor prognosis. Conclusions PTX and DTX were both effective in SLC for ESCC, but their toxicity profiles differed. In terms of febrile neutropenia, PTX seems more appropriate.